Vermelhotin, an Anti-inflammatory Agent, Suppresses Nitric Oxide Production in RAW 264.7 Cells via p38 Inhibition. Pansanit A, Park EJ, Kondratyuk TP, Pezzuto JM, Lirdprapamongkol K, Kittakoop P*. J Nat Prod. 2013 Sep 27;76(9):1824-7.

27 Sep 2013
0
0

Vermelhotin, an Anti-inflammatory Agent, Suppresses Nitric Oxide Production in RAW 264.7 Cells via p38 Inhibition.

Pansanit A, Park EJ, Kondratyuk TP, Pezzuto JM, Lirdprapamongkol K, Kittakoop P*.

J Nat Prod. 2013 Sep 27;76(9):1824-7.

Tags

Share this

Related Posts

JAK2/STAT3‑mediated dose‑dependent cytostatic and cytotoxic effects of sesquiterpene lactones from Gymnanthemum extensum on A549 human lung carcinoma cells. Keeratichamroen S, Lirdprapamongkol K, Thongnest S, Boonsombat J, Chawengrum P, Sornprachum T, Sirirak J, Verathamjamras C, Ornnork N, Ruchirawat S, Svasti J. Oncol Rep. 2022 Jan;47(1):6.
01 Jan 2022
0

JAK2/STAT3‑mediated dose‑dependent cytostatic and cytotoxic effects of sesquiterpene lactones from Gymnanthemum extensum on A549 human lung carcinoma cells. Keeratichamroen S, Lirdprapamongkol K, Thongnest S, Boonsombat J, Chawengrum P, Sornprachum T, Sirirak J, Verathamjamras C, Ornnork N, Ruchirawat S, Svasti J. Oncol Rep. 2022 Jan;47(1):6.

JAK2/STAT3‑mediated dose‑dependent cytostatic and cytotoxic effects of sesquiterpene lactones from Gymnanthemum extensum on A549 human lung carcinoma cells. Keeratichamroen S, Lirdprapamongkol K, Thongnest S, Boonsombat J, Chawengrum P, Sornprachum T, Sirirak J, Verathamjamras C, Ornnork N, Ruchirawat S, Svasti J. Oncol Rep. 2022 Jan;47(1):6.
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
20 Sep 2023
0

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More